Skip to main content

Table 2 Baseline and final study eye characteristics

From: Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: “real life” long-term outcome

 

Baseline

Final

 
 

No. (%)

Mean ± SEM

No. (%)

Mean ± SEM

P value

LogMAR BCVA

 

0.66 ± 0.07

 

0.69 ± 0.07

0.600

BCVA (approximate Snellen equivalent)

 

20/90

 

20/100

 

  20/200 or worse

13 (17.3)

 

15 (20)

  

  Better than 20/200 but worse than 20/40

34 (45.3)

 

33 (44)

  

  20/40 or better

28 (37.3)

 

27 (36)

  

Initial BCVA (ETDRS letters)

     

  <45

66 (88)

 

66 (88)

  

  ≥45

9 (12)

 

9 (12)

  

CPT (microns)

 

369.8 ± 12.5

 

335.9 ± 25.3

0.146

CST (microns)

 

378.4 ± 10.1

 

355.4 ± 20.2

0.142

Intra-retinal fluid

47 (65.3)

 

23 (32)

 

0.038

Sub-retinal fluid

55 (76.4)

 

21 (29.2)

 

0.125

Pigment epithelial detachment

25 (34.7)

 

16 (22.2)

 

0.770

Scar

13 (18.1)

 

37 (51.4)

 

0.013

  1. BCVA = best corrected visual acuity; CPT = central point thickness; CST = central subfield thickness; ETDRS = Early Treatment Diabetic Retinopathy Study; error of the mean; SEM = standard error of the mean. Baseline OCT parameters were available for 72 eyes.